Is Ocriplasmin currently on the market in the country?

As ofSeptember 2025, Ocriplasmin (Ocriplasmin) has not been officially launched in mainland China, which means that domestic patients currently cannot obtain the drug through hospitals, pharmacies or medical insurance channels. The marketing status of Oakplasmin has attracted widespread attention in the field of ophthalmic treatment in China, especially for patients with vitreomacular traction (VMT) or macular holes (MH). The drug provides a non-surgical, innovative treatment option. Its unique mechanism of action is to selectively cleave proteins at the interface between vitreous and retina, thereby relieving traction, improving macular structure and potentially improving vision.

Although it has not yet been launched in China, the clinical data and application experience in overseas markets provide reference for domestic ophthalmologists and patients. In the United States and some European countries, Ocriplasmin has been approved for use in patients with mild to moderate vitreomacular traction and small macular holes. Especially for patients with high surgical risks or who are unwilling to undergo vitrectomy, its non-invasive advantages are obvious. Studies have shown that a single intravitreal injection can significantly improve macular structure within weeks, and some patients are even able to avoid surgical intervention. Overseas safety data also show that common adverse reactions of Ocriplasmin include short-term blurred vision, increased floaters in the eyes, mild eye pain and eye congestion. Most symptoms can heal themselves within a few days, which provides an important reference for future clinical use in China.

Currently, domestic registration and clinical trials ofOcriplasmin are still in the advanced stage. During the approval process, the drug regulatory department will focus on examining its safety, effectiveness and adaptability to the domestic population. At the same time, patient education and postoperative management are also the focus of future promotion, including preoperative OCT image evaluation, intraoperative injection specifications, postoperative follow-up and vision monitoring, which will directly affect the efficacy and safety of the drug.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html